Home/Oxford Biomedica/Dr. Lucinda Crabtree
DL

Dr. Lucinda Crabtree

Chief Financial Officer

Oxford Biomedica

Oxford Biomedica Pipeline

DrugIndicationPhase
Kymriah (Novartis) - LV Vector SupplyB-cell Acute Lymphoblastic Leukemia (ALL), Diffuse Large B-Cell Lymphoma (DLBCL)Approved